JP2021175391A5 - - Google Patents

Download PDF

Info

Publication number
JP2021175391A5
JP2021175391A5 JP2021056390A JP2021056390A JP2021175391A5 JP 2021175391 A5 JP2021175391 A5 JP 2021175391A5 JP 2021056390 A JP2021056390 A JP 2021056390A JP 2021056390 A JP2021056390 A JP 2021056390A JP 2021175391 A5 JP2021175391 A5 JP 2021175391A5
Authority
JP
Japan
Prior art keywords
seq
cdr
amino acid
acid sequence
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021056390A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021175391A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2021175391A publication Critical patent/JP2021175391A/ja
Publication of JP2021175391A5 publication Critical patent/JP2021175391A5/ja
Pending legal-status Critical Current

Links

JP2021056390A 2020-03-31 2021-03-30 免疫活性化多重特異性抗原結合分子およびその使用 Pending JP2021175391A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020062357 2020-03-31
JP2020062357 2020-03-31

Publications (2)

Publication Number Publication Date
JP2021175391A JP2021175391A (ja) 2021-11-04
JP2021175391A5 true JP2021175391A5 (cg-RX-API-DMAC7.html) 2024-04-03

Family

ID=77928944

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021056390A Pending JP2021175391A (ja) 2020-03-31 2021-03-30 免疫活性化多重特異性抗原結合分子およびその使用

Country Status (9)

Country Link
US (1) US20230147840A1 (cg-RX-API-DMAC7.html)
EP (1) EP4126958A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021175391A (cg-RX-API-DMAC7.html)
KR (1) KR20220161156A (cg-RX-API-DMAC7.html)
CN (1) CN115315447A (cg-RX-API-DMAC7.html)
AR (1) AR121692A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202105566TA (cg-RX-API-DMAC7.html)
TW (1) TW202204410A (cg-RX-API-DMAC7.html)
WO (1) WO2021200896A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI736437B (zh) 2010-11-30 2021-08-11 日商中外製藥股份有限公司 細胞傷害誘導治療劑
CA2929044A1 (en) 2013-11-11 2015-05-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified antibody variable region
US11154615B2 (en) 2014-11-11 2021-10-26 Chugai Seiyaku Kabushiki Kaisha Library of antigen-binding molecules including modified antibody variable region
JP7357616B2 (ja) 2017-12-05 2023-10-06 中外製薬株式会社 Cd3およびcd137に結合する改変された抗体可変領域を含む抗原結合分子
WO2019232523A1 (en) * 2018-06-01 2019-12-05 The Board Of Trustees Of The Leland Stanford Junior University Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
WO2023036043A1 (zh) * 2021-09-09 2023-03-16 广东东阳光药业有限公司 抗癌结合分子及其应用
US20250051443A1 (en) * 2021-10-07 2025-02-13 National Research Council Of Canada Anti-cd3 monoclonal antibodies and therapeutic constructs
US20250000976A1 (en) * 2021-10-07 2025-01-02 National Research Council Of Canada Anti-bcma single domain antibodies and therapeutic constructs
US20250376509A1 (en) * 2023-11-21 2025-12-11 Janssen Biotech, Inc. Methods for treatment of myeloproliferative neoplasms
WO2025210181A1 (en) * 2024-04-04 2025-10-09 Cdr-Life Ag Antigen binding proteins targeting an hla-restricted kk-lc-1 peptide
WO2025226541A2 (en) * 2024-04-26 2025-10-30 Janssen Biotech, Inc. Klk2xcd3 antibody and an anti-cancer agent for treating prostate cancer
WO2026086936A1 (en) * 2024-10-24 2026-04-30 Itabmed Co., Ltd. Uses of multispecific antigen binding proteins capable of binding cd19 and cd3
WO2026136923A1 (en) * 2024-12-20 2026-06-25 Vir Biotechnology, Inc. Therapeutic uses of her-2 targeted bispecific polypeptides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI736437B (zh) 2010-11-30 2021-08-11 日商中外製藥股份有限公司 細胞傷害誘導治療劑
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
MX380176B (es) 2014-04-07 2025-03-12 Chugai Pharmaceutical Co Ltd Molecula ligada a antigeno inmunoactivada.
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
JP7357616B2 (ja) * 2017-12-05 2023-10-06 中外製薬株式会社 Cd3およびcd137に結合する改変された抗体可変領域を含む抗原結合分子
JP2022501325A (ja) * 2018-09-28 2022-01-06 中外製薬株式会社 改変された抗体可変領域を含む抗原結合分子
KR20210068079A (ko) * 2018-09-28 2021-06-08 추가이 세이야쿠 가부시키가이샤 Cd3 및 cd137에 결합할 수 있지만 동시에는 결합하지 않는 항원 결합 분자

Similar Documents

Publication Publication Date Title
CN115715202B (zh) 抗体药物缀合物及其制备方法和用途
TWI585104B (zh) 基於vl和vhh可變區衍生物的高親和力抗聚集抗體
JP2022031784A5 (cg-RX-API-DMAC7.html)
JP7031810B2 (ja) 抗pd-1/抗her2天然抗体構造形態のヘテロダイマー系二重特異性抗体及びその製造方法
FI3802598T3 (fi) Dll3/cd3:a sitovia proteiineja syövän hoitamiseksi
JP2021159081A5 (cg-RX-API-DMAC7.html)
JP2022009816A5 (cg-RX-API-DMAC7.html)
US11987609B2 (en) Proteinaceous heterodimer and use thereof
CN113195530B (zh) 抗体融合蛋白、制备方法及其应用
CN118063619A (zh) 工程化的异源二聚体蛋白质
AU2021390121A9 (en) Anti-human b7-h3 antibody and application thereof
JP2021513366A (ja) 抗pd−1/抗her2天然抗体構造ヘテロダイマー系の二重特異性抗体及びその製造方法
WO2021168194A1 (en) Engineered anti-her2 bispecific proteins
JP2022537823A (ja) 共有結合型多重特異性抗体
JP2024507693A5 (cg-RX-API-DMAC7.html)
TW202222824A (zh) Egfr結合複合物及其製備和使用方法
WO2023246701A1 (zh) 一种抗体及其用途
Schilz et al. Molecular recognition of structurally disordered Pro/Ala-rich sequences (PAS) by antibodies involves an Ala residue at the hot spot of the epitope
WO2024131949A1 (zh) Anti-cMet抗体、抗体药物偶联物及其制备方法和用途
WO2020192648A1 (en) Proteinaceous heterodimer and use thereof
JP2021522793A5 (cg-RX-API-DMAC7.html)
CN112159473A (zh) 重组人源化抗人白介素23单克隆抗体的纯化方法
CN108290942A (zh) 与人及小鼠信号素3a交联的抗体及其用途
CN118754989A (zh) 一种抗her2纳米抗体及其制备方法和应用
CN120659804A (zh) 多价蛋白质及筛选方法